There is a growing awareness that the unintended, adverse health effects of cholesterol-lowering statin drugs far outweigh their purported benefits. But now new research indicates that these drugs may even interfere with the heart-protective effects of omega-3 fatty acids in those who are taking them.
A new study published in the journal BMC Medicine is shedding much needed light on why the widely publicized fish oil study released late last year in the Journal of the American Medical Association, which diverged from earlier randomized controlled trials (RCTs) demonstrating the health benefits of omega-3 fatty acids, showed no evidence of cardiovascular disease risk reduction associated with omega-3 intake.
In the new study, researchers at the Joseph Fourier University in Grenoble, France proposed that more recent RCTs on fish oil and heart health that have reported negative findings, like the JAMA study, can be explained by two hidden confounding variables:
- Today, with both increased awareness of the health benefits and increased consumption of omega-3 fats, the vast majority of participants in these newer controlled trials are no longer as omega-3 fat deficient and therefore may not show as great (if any) measurable beneficial effect when given additional supplemented omega-3.
- The vast majority of contemporary RCT study participants are also on statin drugs, which suppress the beneficial properties of omega-3 fatty acids within the body, making negative findings more likely.[i]
The second confounding variable, that statins suppress omega-3 fatty acid benefits, is the most groundbreaking, as very few doctors or patients are aware of this possibility. On the other hand, statins exert such a broad range of adverse health effects in the body, including major deficiencies of zinc, copper, selenium, coq10, vitamin E, and possibly vitamin D, as well, that we shouldn't be all that surprised.[ii]
In support of their hypothesis they cite research indicating that statin drugs favor the metabolism of omega-6 fatty acids, which in turn inhibit omega-3 fatty acids; essentially omega-6 and omega-3 compete with one another for the same metabolic enzymes, indicating that the ratio in the diet is more important than absolute values.[iii] Also, omega-6 fats, contrary to omega-3's, increase insulin resistance, increasing the risk of diabetes. This may explain the well-known diabetogenic properties of statin drugs.[iv]
An over preponderance of omega-6 fats have also been linked to inflammatory health conditions and cancer,[v] which may be due to the role they play in the excessive formation of arachidonic acid, a substrate for inflammation-associated enzymes COX2 and LOX, as well as contributing to the downstream formation of many inflammatory hormones in the body, e.g. PGE2, thromboxane, leukotriene, etc.
Since most of prescribed cholesterol-lowering drugs on the market increase the blood concentration of arachidonic, it is quite possible that statin-induced dysregulation of omega-3/omega-6 production, their ratio and metabolism, may contribute to a whole host of adverse health effects. Indeed, the biomedical literature signals over 300 health problems caused by this chemical class of drugs.[vi]